Hyperfine, Inc. Class A (HYPR)

Several events have impacted Hyperfine, Inc.'s stock price in the past six months. Hyperfine reported strong fourth-quarter 2025 revenue and provided 2026 revenue guidance, extending its cash runway into 2028. Horizon Technology Finance provided a $40 million loan facility to Hyperfine. The Chief Operating Officer and Chief Financial Officer sold shares of Hyperfine stock in March 2026. Hyperfine received regulatory clearances for its updated products, indicating continued innovation and market access. The announcement of the Hyperfine Swoop® System as India's first portable MRI for bedside brain imaging was a positive development for global expansion. Investor anticipation surrounded the upcoming first-quarter 2026 financial results.

While there is strong and growing demand for Hyperfine's Swoop system and OptiveAI software, there is no explicit information detailing specific demand seasonality for its products and services. The company's focus on critical care, emergency settings, and neurology offices suggests a consistent need for its imaging solutions, rather than a highly seasonal demand pattern.

Hyperfine, Inc. is a health technology company focused on revolutionizing brain imaging through its portable MRI system, operating within the Healthcare sector, specifically in the Medical Devices and Electromedical and Electrotherapeutic Apparatus Manufacturing industries. The company's core business revolves around the production, supply, service, and commercialization of MRI products, with its flagship product being the Swoop® Portable MR Imaging® System, an FDA-cleared, AI-powered, ultra-low-field MRI system designed for brain imaging at the point of care. Hyperfine also offers the Hyperfine Image Viewer, a cloud picture archiving and communication system, and its Optive AI™ software, which powers the next-generation Swoop system. The company's business model combines device sales with ongoing service and software revenue, including subscriptions and maintenance.

Hyperfine, Inc. has a growing global presence, serving customers through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. Recent expansions include regulatory approval in India for the Swoop® system, authorizing its commercialization in the country. Distribution agreements have also been established in Turkey, Israel, and Saudi Arabia, further broadening Hyperfine's reach across North America, Europe, Asia, Oceania, and the Middle East.

Hyperfine's brand reputation in the past year appears to be positively influenced by its innovative technology and expanding market reach. The company has received FDA clearance for its Swoop® system for brain imaging of patients of all ages, and more recently, CE and UKCA Marks for its next-generation Swoop® System and Optive AI™ Software. The introduction of the Swoop® system as India's first portable MRI for bedside brain imaging and new distribution partnerships in European and Middle Eastern markets demonstrate growing international acceptance and demand for its technology. Hyperfine emphasizes clinical studies and health economic analyses, and its continuous development of AI-powered software reinforces its commitment to innovation in diagnostic imaging.

Hyperfine, Inc. is owned by a mix of institutional shareholders, company insiders, and retail investors. Major institutional owners include Vanguard Group Inc, Sio Capital Management, LLC, Fosun International Ltd, Northern Trust Corp, Catalio Capital Management, LP, Alphabet Inc., Geode Capital Management, Llc, BlackRock, Inc., Jane Street Group, Llc and Renaissance Technologies Llc. Major individual and insider owners include Jonathan M. Rothberg, HC Sponsor LLC and David D. Scott. Insiders collectively own approximately 26.33% of the stock.